Overview

Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)

Status:
Completed

Trial end date:
2011-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the clinical efficacy, safety, and tolerability of a 250 mg BID oral dose of JNJ-32729463 compared with linezolid in subjects with complicated skin and skin structure infections (cSSSIs).

Phase:

Phase 2

Details

Lead Sponsor:

Furiex Pharmaceuticals, Inc

Treatments:

Linezolid